Medical company BIOTRONIK revealed on Thursday that the Acticor and Rivacor high-voltage cardiac rhythm management (CRM) devices have passed the US FDA's approval for treatment of patients with cardiac arrhythmias, with availability in the US in April 2019.

According to the companies, the six new tachycardia solutions include Rivacor VR-T, Rivacor DR-T, Rivacor HF-T QP, Acticor DX, Acticor CRT-DX Bipolar and Acticor CRT-DX.

The company stated that the Acticor and Rivacor systems are designed to incorporate more diagnostic and therapeutic capabilities in smaller devices with extended battery longevity, which provides physicians with more comprehensive therapy options when treating cardiac patients with varying disease states and comorbidities.

With a smooth, elliptical BIOshape, Acticor and Rivacor devices are the smallest and slimmest 3 Tesla (3T) MR-conditional CRM devices on the market. The ultraslim devices have rounded edges that lessen skin pressure and help to lower the risk of skin erosion while increasing patient comfort. The devices are backed by extended warranties, disclosed the company.

Both device families are equipped with BIOTRONIK Home Monitoring and the proven DX technology can detect silent atrial fibrillation for stroke prevention, enhance diagnostic accuracy for better clinical decision-making and allow for dual-chamber supraventricular tachycardia (SVT) discrimination to prevent unnecessary shocks, enables faster procedure times, lowers cost as well as reduces complications, added the company.